Physician profile
John C Elser
NPI 1154366839
$6,070.07
in general payments reported to CMS, 2019-2025
28 companies · $14.02 in 2025
The $14.02 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,923 · 2020: $1,805 · 2021: $1,089 · 2022: $130 · 2023: $36.36 · 2024: $73.03 · 2025: $14.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $773.48 | 2019-2021 | |
| Pfizer INC. | $730.36 | 2019-2021 | |
| Novo Nordisk INC | $622.05 | 2019-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $579.25 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $572.72 | 2019-2021 | |
| Amgen INC. | $501.44 | 2019-2025 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.15 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $344.69 | 2019-2021 | |
| Amarin Pharma, INC. | $230.19 | 2019-2021 | |
| Allergan, INC. | $156.10 | 2020 | |
| Glaxosmithkline, LLC. | $152.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $149.04 | 2019-2021 | |
| Astellas Pharma US INC | $105.88 | 2019-2021 | |
| Mylan Specialty L.P. | $102.98 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $95.64 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $79.29 | 2019-2023 | Eliquis |
| Abbvie INC. | $66.99 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $59.71 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.20 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $41.68 | 2021 | |
| Collegium Pharmaceutical, INC. | $34.62 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $34.07 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.53 | 2021 | |
| Sanofi Pasteur INC. | $22.83 | 2019 | |
| Abbott Laboratories | $22.41 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.46 | 2019 | |
| Hikma Pharmaceuticals USA | $13.82 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Elser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.